CTI Thermal Breast Imaging Device Will Go Before FDA Panel In Mid-October
This article was originally published in The Gray Sheet
Executive Summary
FDA's decision to bring Computerized Thermal Imaging's BCS 2100 thermal breast imaging system before an advisory panel upholds the integrity of the PMA filing and disproves allegations that the firm unlawfully tampered with the submission, according to CTI